New RATS to launch soon

- Differences
- Benefits
- User Population
- User Interface
- Smartform
- User Training
Differences

Top down Narrative Approach

RATS

1. What is the Title of the Project?
   Select Top down Narrative

2. Check all that apply:
   - TOP down Narrative (e.g., project)
   - Substances (e.g., chemicals, RECs, animal protocols, etc.)
   - Procedures (e.g., animal care, cellular procedures, etc.)
   - External Narrative (e.g., government, funding)
   - Other Narrative (e.g., other issues)

3. Are there any other narrative issues?
   - Yes
   - No

4. Check all that apply:
   - Procedures are not used exclusively as an assurance tool
   - Substances are not used exclusively as an assurance tool

5. If you are seeking an assurance, what is the assurance?
   - Yes
   - No

Bottom up Building Block Approach

New RATS

1. Create Procedures
   - Procedure: Substance
   - Substance: Procedure

2. Create Experiments using Procedures and Substances
   - Protocol Experiment
     - Procedure: Substance
     - Substance: Procedure

UCLA Substances & Procedures Library

- Substances
- Procedures

Research Team

- Substances
- Procedures
## Benefits

<table>
<thead>
<tr>
<th>PIs</th>
<th>Reviewers &amp; Committee</th>
<th>Central Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Decreases submission effort</td>
<td>• Updated review process</td>
<td>• Centralizes and improves the review process</td>
</tr>
<tr>
<td>• Improves overall experience</td>
<td>• Improves collaboration</td>
<td>• Provides a voice in Huron product direction for future upgrades</td>
</tr>
<tr>
<td>• Promotes reusability of substances and procedures</td>
<td>• Reduces manual paper processes</td>
<td></td>
</tr>
</tbody>
</table>

---

**UCLA Research Administration**
User Population

- 82 PIs with no Click Experience (19%)
- 160 PIs with webIRB Experience (46%)
- 135 PIs with IBC Experience (34%)
- 46 PIs with both IBC and webIRB Experience (13%)

PIS with no Click Experience
- PIs with IBC Experience
- PIs with webIRB Experience
- PIs with both IBC and webIRB Experience
User Interface

TEAM00000036
Jennifer Perkins Team
Principal investigator: JENNIFER PERKINS
Phone: 3107949645
E-mail: jperkins@research.ucla.edu

Active
Next Steps
- Edit Research Team
- Create Protocol
- Create Procedure
- Create Substance

Filter by
- ID
- Enter text to search for

No data to display.

Submissions | Procedures | Substances | History | Research Team Contacts | Archived Procedures | Archived Substances | Training
---|---|---|---|---|---|---|---

page 1 no results
User Interface

TEAM00000036

Jennifer Perkins Team

Principal Investigator: JENNIFER PERKINS
Phone: 310-794-9645
E-mail: jperkins@research.ucla.edu

<table>
<thead>
<tr>
<th>Name</th>
<th>Execute Activity</th>
<th>Date Modified</th>
<th>State</th>
<th>Version</th>
<th>Species</th>
<th>Procedure Type</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEST</td>
<td>Actions</td>
<td>11/7/2019 9:26 AM</td>
<td>Active</td>
<td>1</td>
<td>Rat</td>
<td>Substance Administration</td>
<td>Team</td>
</tr>
<tr>
<td>Anesthetic Overdose, AQUI-S 20E (10% Eugenol)</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Fish</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Rat</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Gerbil</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Mouse</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Hamster</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Guinea Pig</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Dog</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Rabbit</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Rhesus Macaque</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
<tr>
<td>Anesthetic Overdose, Pentobarbital or Pentobarbital Solution</td>
<td>Actions</td>
<td>9/13/2018 12:28 PM</td>
<td>Active</td>
<td>1</td>
<td>Pig</td>
<td>Euthanasia</td>
<td>Standard</td>
</tr>
</tbody>
</table>
# User Interface

**TEAM0000036**

**Jennifer Perkins Team**

**Principal Investigator:** JENNIFER PERKINS  
Phone: 3107949645  
E-mail: jperkins@research.ucla.edu

## Submissions Table

<table>
<thead>
<tr>
<th>Name</th>
<th>Date Modified</th>
<th>Type</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,2,4-Tribromo-5-(2,4-dibromophenox)benzene (DE-71)</td>
<td>2/11/2020 6:46 PM</td>
<td>Other</td>
<td>Standard</td>
</tr>
<tr>
<td>1-Methyl-4-phenyl-1,2,3,6-tetrahydrophrydine (MPTF)</td>
<td>9/20/2018 3:39 PM</td>
<td>Other</td>
<td>Standard</td>
</tr>
<tr>
<td>Mercaptothene Sulfonate Na (Mesna, Uromitexan, Mesnex)</td>
<td>9/20/2018 3:38 PM</td>
<td>Chemical Agent, Other</td>
<td>Standard</td>
</tr>
<tr>
<td>4-Hydroxycyclophosphamide</td>
<td>9/20/2018 3:38 PM</td>
<td>Reproductive Hazard/Teratogen, Chemotherapeutic or Other Hazardous Drug</td>
<td>Standard</td>
</tr>
<tr>
<td>4-Hydroxy-tamoxifen (tamoxifen, 40HT)</td>
<td>9/20/2018 3:42 PM</td>
<td>Chemical Agent, Reproductive Hazard/Teratogen, Chemotherapeutic or Other Hazardous Drug, Hormonal Regulator</td>
<td>Standard</td>
</tr>
<tr>
<td>Ipomeanol (IPO, 1 pentanone, 4-hydroxypentanone)</td>
<td>9/20/2018 3:42 PM</td>
<td>Toxin of biological origin</td>
<td>Standard</td>
</tr>
<tr>
<td>4-nonylphenol (4-(2,4-dimethylheptan-3-yl)phenol)</td>
<td>9/20/2018 3:41 PM</td>
<td>Chemical Agent</td>
<td>Standard</td>
</tr>
<tr>
<td>(N,N-hexamethylen)amiloride (hexamethylenamiloride)</td>
<td>9/20/2018 3:44 PM</td>
<td>Chemical Agent, Antiviral</td>
<td>Standard</td>
</tr>
<tr>
<td>Bromodeoxyuridine (BrdU, 5-bromo-2-deoxyuridine)</td>
<td>9/20/2018 3:41 PM</td>
<td>Chemical Agent, Antiviral, DNA/RNA</td>
<td>Standard</td>
</tr>
<tr>
<td>Fluorocytosine (Flucytosine, ancobon)</td>
<td>9/20/2018 3:38 PM</td>
<td>Reproductive Hazard/Teratogen, DNA/RNA, Antifungal Agent</td>
<td>Standard</td>
</tr>
<tr>
<td>Fluorouracil (fluorouracil, Adriquill)</td>
<td>9/20/2018 3:40 PM</td>
<td>Chemical Agent, Reproductive Hazard/Teratogen, Chemotherapeutic or Other Hazardous Drug, DNA/RNA</td>
<td>Standard</td>
</tr>
<tr>
<td>Lipoygenase inhibitor</td>
<td>9/20/2018 3:43 PM</td>
<td>Reproductive Hazard/Teratogen, Toxin of biological origin, Analgesic</td>
<td>Standard</td>
</tr>
</tbody>
</table>
## User Interface

### Active

**Next Steps**
- Edit Research Team
- Create Protocol
- Create Procedure
- Create Substance

**TEAM00000036**

**Jennifer Perkins Team**

Principal Investigator: JENNIFER PERKINS
Phone: 3107949453
E-mail: jperkins@research.ucla.edu

### Filter by

#### Name

<table>
<thead>
<tr>
<th>Name</th>
<th>Date Modified</th>
<th>Type</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine HCl (Buprenex, Simbadol)</td>
<td>10/11/2018 8:52 AM</td>
<td>Reproductive Hazard/Teratogen, Analgesic</td>
<td>Standard</td>
</tr>
<tr>
<td>Buprenorphine (Oxybuprocaine, Altafluor, Fluvex)</td>
<td>9/20/2018 3:38 PM</td>
<td>Anesthetic</td>
<td>Standard</td>
</tr>
<tr>
<td>Buprenorphine SR (Zoopharm)</td>
<td>9/20/2018 3:43 PM</td>
<td>Reproductive Hazard/Teratogen, Analgesic</td>
<td>Standard</td>
</tr>
<tr>
<td>Ibuprofen (Motrin, Advil)</td>
<td>9/20/2018 3:45 PM</td>
<td>Reproductive Hazard/Teratogen, Analgesic</td>
<td>Standard</td>
</tr>
</tbody>
</table>

4 Items

**page 1 of 1**
1. **Experiment name:**
   - Experiment 1

2. **Species:**
   - Mouse

3. **Briefly explain the scientific goal of this experiment:**
   - Experimental Goals

4. **Describe the experiment:**
   - For any given group/cohort, describe what any given animal will experience from initiation of the study to euthanasia, including order and minimal time between procedures. Detailed procedural descriptions and animal numbers are not needed here as they will both be provided below.
5. Select experimental procedures, including euthanasia methods:

6. Table of Animals:
   - Note: the calculator will multiply the group size by the number of animals for the experiment.

   a. * Explain how you estimated the appropriate sample size for the study. In addition, please provide an estimation of the number of animals to be used per individual data point, including pilot data or data from previous studies.

   - Power analysis was conducted using values from the literature.
   - Effect size based on pilot data or data from previous experiments.
   - Group sizes were selected based on data from the power analysis.
   - This is a pilot study for which there are no previous studies to estimate group size. Data collected from pilot experiments.
   - No statistical comparisons are planned. This is a qualitative or methodological feasibility study using the minimum number of animals from which reliable conclusions can be reasonably expected to be drawn.

   - Other (Please elaborate in the box below)
7. Number of animals by pain category: place all non-USDA regulated species in N: (include each animal only once in the highest pain category)

N: 
B: 
C: 
D: 
E: 

a. Justify the need for any animals in pain category E.

8. Identify husbandry exceptions:

9. * Should DLAM need to treat your animals in the event of a reported clinical event or emergency, are there substances (e.g. NSAIDS or other analgesics, antibiotics, etc.) that should not be used?
   ○ Yes  ○ No  Clear
• User training dates

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
<th>Capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/25 Tuesday</td>
<td>2:00 – 3:30 PM</td>
<td>Wilshire-Glendon Building* 10889 Wilshire, room 820-20</td>
<td>16</td>
</tr>
<tr>
<td>2/28 Friday</td>
<td>2:30 – 4:00 PM</td>
<td>Biomedical Library 6th Floor, TLC Classroom</td>
<td>30</td>
</tr>
<tr>
<td>3/10 Tuesday</td>
<td>1:30 – 3:00 PM</td>
<td>Biomedical Library 6th Floor, TLC Classroom</td>
<td>30</td>
</tr>
<tr>
<td>3/11 Wednesday</td>
<td>2:30 – 4:00 PM</td>
<td>Biomedical Library 6th Floor, TLC Classroom</td>
<td>30</td>
</tr>
</tbody>
</table>
• ARC Staff: arc@research.ucla.edu or 310-206-6308
• IBC Staff: ibc@research.ucla.edu or 310-794-0262
• RSC Staff: rsc@research.ucla.edu or 310-206-5601
• RSAWA Director: jperkins@research.ucla.edu or 310-794-9645